{"id":"W4319660730","doi":"10.1016/s0140-6736(22)02406-0","title":"An investigational oral plasma kallikrein inhibitor for on-demand treatment of hereditary angioedema: a two-part, randomised, double-blind, placebo-controlled, crossover phase 2 trial","year":2023,"lang":"en","type":"article","venue":"The Lancet","topic":"Coagulation, Bradykinin, Polyphosphates, and Angioedema","field":"Medicine","cited_by":51,"is_retracted":false,"has_abstract":false,"ca_institutions":"University of Toronto","funders":"Grifols; University of Toronto; Alnylam Pharmaceuticals; BioCryst; Regeneron Pharmaceuticals; CSL Behring; Pfizer","keywords":"Hereditary angioedema; Medicine; Placebo; Clinical endpoint; Angioedema; Crossover study; Pharmacokinetics; Clinical trial; Internal medicine; Pharmacodynamics; Randomized controlled trial; Dermatology; Alternative medicine; Pathology","routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009068153,0.0003177717,0.001269274,0.0001432479,0.000230873,0.00005378085,0.0001745002,0.0001245542,0.0001305527],"category_scores_gemma":[0.0001755171,0.0002012308,0.000453525,0.0002616719,0.0002117535,0.0001395405,0.00001871791,0.00009422405,0.00003820068],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00007280692,"about_ca_system_score_gemma":0.0002582544,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00005715851,"about_ca_topic_score_gemma":0.00005717883,"domain_scores_codex":[0.9978794,0.0001306233,0.0007035986,0.0003872163,0.000438534,0.0004606323],"domain_scores_gemma":[0.9978876,0.0009506679,0.0002895567,0.0005457528,0.0001185384,0.0002079379],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9617386,0.0008802397,0.00030051,0.00004840073,0.0005541118,0.00002282156,0.0007359086,0.000862245,0.0008994633,0.001057823,0.03165613,0.001243677],"study_design_scores_gemma":[0.9672567,0.004015317,0.0001771422,0.00009092627,0.0005231004,0.00001559547,0.00008567818,0.01083735,0.007904607,0.001015189,0.007872356,0.000206034],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9893993,0.0003501826,0.00003740304,0.002848243,0.000864708,0.005485724,0.0003350602,0.0001613387,0.0005181076],"genre_scores_gemma":[0.9843077,0.00006514806,0.0003045702,0.000482338,0.009464025,0.001482952,0.001021766,0.0000568145,0.002814695],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.02378377,"threshold_uncertainty_score":0.8205954,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1007508725685694,"score_gpt":0.3749197365572001,"score_spread":0.2741688639886307,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}